Feed RNA
RN

Avidity Biosciences

RNA · NASDAQ

$10.09 -1.18% (-$0.12)
1M -22.15%
Piotroski F-Score Weak
2/9
Valuation
-
N/A
EV/FFO N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A
ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A
Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
42 /100
Moderate
Beta 0.37x
EPS volatility N/A
Profitable years N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre RNA
Online

Despre companie

Avidity Biosciences is a biotechnology company focused on developing advanced therapeutic methods using targeted RNA-based therapies. The company specializes in creating therapeutic products that leverage its proprietary technologies to selectively deliver therapeutic molecules to specific cells, offering a new approach to treating diseases caused by genetic mutations. Avidity focuses on treating diseases such as Duchenne muscular dystrophy and other genetic disorders that previously lacked effective treatments.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Kathleen Gallagher

Employees

511

Headquarters

San Diego

Evenimente viitoare

12 NOV.

Earnings

Upcoming earnings report

57d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.